Copper Rallies on Growing Supply Concerns

Source: Copper Investing News, Lei Toovey (1/18/11)

"Copper has jumped 30% in past 12 months."

Copper futures rallied on mounting concerns that demand will outpace global supplies by as much as 600,000 tons (600 Kt.) in 2011. In New York, copper futures for March delivery rose 0.3%, to $4.427 at 10:44 a.m. on the Comex. Over on the LME, copper for delivery in three months rose $60, or 0.6%, to $9,690 a ton ($4.40/lb.).

Copper has jumped 30% in past 12 months. The red metal reached a record of $4.498/lb. on Jan. 3. The price may average $5.10 this year, up 49% from 2010, Bank of America Merrill Lynch analysts said today in a report. "Copper has the strongest fundamentals among the base metals. The concentrates and scrap markets remain tight, and mine supply will likely constrain refined output in the coming years. We forecast a deficit for 2011," said Merrill Lynch analysts.

According to JP Morgan Securities, the copper deficit will be from 500–600 Kt. in 2011. Macquarie said in a research report on Dec. 27 that the shortfall would be 550,000 tons. The International Copper Study Group has predicted a shortage of 435,000 tons. Today, Morgan Stanley today raised its copper and gold forecasts through 2015. The bank wrote in a research report that copper is likely to average $4.45/lb. in 2011, up 24% from an earlier estimate.

Several of Chile's largest private mining companies have opted for the country's new copper royalty structure, Mining Minister Laurence Golborne said Wednesday. The government moved to increase the royalty copper miners were paying to in part finance reconstruction efforts following the 8.8-magnitude quake that ravaged the country in early 2010. Under the new structure, which is voluntary, copper producers could pay a royalty of up to 14%, based on their sales and world copper prices.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.